SRDX - Earnings announcements

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $31.3 million, an increase of 17% year-over-year GAAP net loss of $(3.4) million, compared to net income of $6.7 million in the prior-year period Adjusted EBITDA(2) of $4.4 million, compared to $1.7 million in the prior-year period Fiscal 2024 Financial Summa

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in the prior-year period which included $24.6 million in license fee revenue recognized upon receipt of a $27.0 million milestone payment associated with obtaining FDA premarket approval of the SurVeil™ drug-coated balloon ("DCB") Total Revenue excluding SurVeil DCB license fee revenue(1) of $29.2 million, an increase of 10% year-over-year GAAP net loss of $(7.6) million, co

Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary Total Revenue of $32.0 million, an increase of 18% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $30.9 million, an increase of 19% year-over-year GAAP

Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second quarter fiscal 2024 financial results and accomplishments and host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the Company's website at https://surmodi

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024. First Quarter Fiscal 2024 Financial Summary Total Revenue of $30.6 million, an increase of 23% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 25% year-over-year GAAP net loss of $(0.8) million, compared to $(7.8) million in the prior-year period Adjusted EBITDA(2) of $3.9 million, compared to $(3.3) million

Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Thursday, February 1, to discuss the first quarter fiscal 2024 financial results and accomplishments and host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the Company's website at https://s

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024. Fourth Quarter Fiscal 2023 Financial Summary Total Revenue of $28.0 million, an increase of 8% year-over-year Total Revenue excluding SurVeil™ DCB license fee revenue(1) of $26.9 million, an increase of 12% year-over-year GAAP Diluted EPS of $0.47, compared to $(1.06) in the prior-year period Non-GAAP Diluted EPS of $0.53, compared to $(0.26) in the prior-year period

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, November 8. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, November 8, to discuss the fourth quarter of fiscal 2023 financial results and accomplishments, and to host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the company's website

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Third Quarter Fiscal 2023 Financial Summary Total Revenue of $52.5 million, an increase of 111% year-over-year Recognized $24.6 million in license fee revenue upon receipt of a $27.0 million milestone payment associated with obtaining FDA premarket approval of the SurVeil™ DCB under the company's Development and Distribution Agreement with Abbott GAAP Diluted EPS of $0.52, compared to $(0.41) i

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that third quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, August 2. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, August 2, to discuss the third quarter of fiscal 2023 financial results and accomplishments, and to host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the company's website at ht

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Second Quarter Fiscal 2023 Financial Summary Total Revenue of $27.2 million, an increase of 4% year-over-year GAAP Diluted EPS of $(0.55), compared to $(0.29) in the prior-year period Non-GAAP Diluted EPS of $(0.40), compared to $(0.22) in the prior-year period Second Quarter and Recent Business Highlights On January 19, 2023, Surmodics announced it received a letter from the U.S. Food

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, April 26, to discuss the second quarter of fiscal 2023 financial results and accomplishments, and to host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the company's website at

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023. First Quarter Fiscal 2023 Financial Summary Total Revenue of $24.9 million, an increase of 8% year-over-year GAAP Diluted EPS of $(0.56), compared to $(0.20) in the prior-year period Non-GAAP Diluted EPS of $(0.50), compared to $(0.13) in the prior-year period First Quarter and Recent Business Highlights On October 13, 2022, Surmodics submitted a complete response to U.S. Food and Drug Admin

Earnings Conference Call and Webcast Will Begin at 4:00 p.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6. Management will host a live webcast and conference call at 4:00 p.m. CT (5:00 p.m. ET) on Monday, February 6, to discuss the first quarter fiscal 2023 financial results and accomplishments and host a question-and-answer session. To access the webcast, please go to "Events & Presentations" under the "Investors" section of the Company's website at https://surmo

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2022, and introduced its financial outlook for the fiscal year ending September 30, 2023. Fourth Quarter 2022 Financial Summary Total Revenue of $26.0 million, an increase of 8% year-over-year GAAP Diluted EPS of $(1.06), including $(0.73) deferred tax valuation reserve, compared to $(0.02) in the prior-year period Non-GAAP Diluted EPS of $(0.26), compared to $(0.10) in the prior-year period Fiscal Year 2022 Financial Summary Total Revenue of $100.0 million,

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Wednesday, November 9th. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, November 9th, to discuss the fourth quarter fiscal 2022 financial results and accomplishments and host a question-and-answer session. To access the webcast, navigate to upcoming events under the ‘events and presentations' tab within the investor relati

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended June 30, 2022 and updated its financial outlook for its fiscal 2022. Summary of Third Quarter and Recent Highlights Revenue of $24.9 million, an increase of 4% year-over-year GAAP EPS of $(0.41), non-GAAP EPS of $(0.34) Fourth consecutive quarter of double‐digit product sales growth year‐over‐year "We delivered solid financial results that were in line with our expectations, while continuing to make meaningful investments in our growth initiatives," said Gary Maharaj, President and CEO of

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2022 conference call on Wednesday, July 27, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning. Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the third quarter fiscal 2022 financial results and accomplishments. To access the webcast, navigate to upcoming events under the events and presentat

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022. Summary of Second Quarter and Recent Highlights Revenue of $26.1 million, a sequential increase of 13% Record In Vitro Diagnostics revenue of $7.7 million GAAP EPS of $(0.29), non-GAAP EPS of $(0.22) Double-digit product sales growth year-over-year from both Medical Device and In Vitro Diagnostics businesses "In our second quarter, we continued to grow our customer pipeline and secure new customer accounts for our Su

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2022 conference call on Wednesday, April 27, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning. Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the second quarter fiscal 2022 financial results and accomplishments. To access the webcast, navigate to upcoming events under the events and presen

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 million, an increase of 3% year-over-year GAAP EPS of $(0.20), non-GAAP EPS of $(0.13) First commercial sale of Pounce™ Arterial Thrombo-embolectomy System "I am pleased with our first quarter performance. We delivered revenue growth and made critical progress on our SurVeil™ drug-coated balloon PMA submission and early commercialization of our Sublime™ radial and Pounce™ arterial thrombectomy platforms," s

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2022 conference call on Thursday, February 3, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning. Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the first quarter fiscal 2022 financial results and accomplishments. To access the webcast, navigate to upcoming events under the events and present

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022. Summary of Fourth Quarter and Recent Highlights Revenue of $24.0 million, an increase of 6% year-over-year GAAP EPS of $(0.02), non-GAAP EPS of $(0.10) Successful first patient use Sublime™ .018 RX PTA Dilatation Catheter "We're extremely pleased to share that the Sublime™ and Pounce™ clinical product evaluations are confirming the meaningful advantages of our radial access and arterial thrombectomy products," sai

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2021 conference call on Wednesday, November 10, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning. Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the fourth quarter fiscal 2021 financial results and accomplishments. To access the webcast, navigate to upcoming events under the events and pre

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 third quarter ended June 30, 2021 and updated its financial outlook for its fiscal 2021. Summary of Third Quarter and Recent Highlights Revenue of $23.9 million, a decrease of 11% year-over-year GAAP EPS of $(0.24), non-GAAP EPS of $(0.17) PMA submission completed for SurVeil™ drug-coated balloon FDA 510(k) clearance received for Sublime™ .018 RX PTA Dilatation Catheter Successful first patient use of Pounce™ Thrombectomy System for arterial clot removal FDA 510(k) clearance received on expanded indicati

Webcast is Live at 7:30 a.m. (CT) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2021 conference call on Wednesday, August 4, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning. Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the third quarter fiscal 2021 financial results and accomplishments. To access the webcast, you can click here or by dialing 800-496-3710 and enterin